Reaction
Rebound Atopic Dermatitis reporting signals
As of the last recalculation, Rebound Atopic Dermatitis appears in 2,012 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is DUPILUMAB (PRR 12,087.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dupilumab | 2,005 | 12,087.9 | 12,138.7 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 35 | 15.7 | 15.7 |
| Clobetasol Propionate Ointment Usp, 0.05% | 13 | 13.1 | 13.2 |
| Clobetasol Propionate | 13 | 13.1 | 13.1 |
| Triamcinolone Acetonide | 35 | 11.9 | 11.9 |
| Hydroxyzine Hydrochloride | 13 | 10.3 | 10.3 |
| Hydroxyzine Hydrochloride Oral | 13 | 10.3 | 10.3 |
| Tretinoin | 6 | 7.7 | 7.7 |
| Crisaborole | 6 | 6.5 | 6.5 |
| Nemolizumab-Ilto | 6 | 4.9 | 4.9 |
| Fexofenadine Hydrochloride | 10 | 4.8 | 4.8 |